Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

FcRn Antagonists (Efgartigimod) for Acute Neuromyelitis Optica Spectrum Disorders (NMOSD) Attack: a Phase 2, Randomized Controlled Trial.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06497374
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:23.027071+00:00
Published At
2024-07-11T00:00:00+00:00
Record Updated At
2024-07-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Neuromyelitis Optica", "Neuromyelitis Optica Spectrum Disorder", "NMO Spectrum Disorder"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-07-11"
protocolSection.identificationModule.nctId
"NCT06497374"
protocolSection.identificationModule.officialTitle
"FcRn Antagonists (Efgartigimod) for Acute Neuromyelitis Optica Spectrum Disorders (NMOSD) Attack: a Phase 2, Randomized Controlled Trial."
protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Neuromyelitis Optica (protocolSection.conditionsModule.conditions)
  • Neuromyelitis Optica Spectrum Disorder (protocolSection.conditionsModule.conditions)
  • NMO Spectrum Disorder (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.